Why AST SpaceMobile Stock Is Sinking Today
AST SpaceMobile opened Tuesday's trading with big sell-offs, but it has seen a significant recovery as the day has progressed.
The satellite communications company's share price fell in response to Lockheed's Q2 report and analyst coverage on BlackSky Technology.
AST's share price has bounced back from early sell-offs following news about the U.S.'s "Golden Dome" missile defense system.
10 stocks we like better than AST SpaceMobile ›
AST SpaceMobile (NASDAQ: ASTS) stock is losing ground in Tuesday's trading, although it has also seen a big recovery from its low in the session. The company's share price was down 1.9% as of 2 p.m. ET but had been down as much as 9.6% earlier in the day.
The broader market saw strong bearish momentum early in today's session, with sell-offs concentrated in the tech sector, but the pullback has moderated as the day has progressed. In addition to valuation pressures impacting growth-dependent tech stocks, AST stock appears to have been negatively impacted by Lockheed Martin's disappointing earnings report and analyst coverage on fellow space industry player BlackSky Technology.
Lockheed's Q2 results are weighing on AST stock
Lockheed Martin published its second-quarter results before the market opened this morning, and the market has had a strong bearish reaction to the numbers. While the aerospace and defense giant's non-GAAP (adjusted) earnings per share of $7.29 beat the average analyst estimate by $0.82 per share, sales of $18.16 billion in the period missed Wall Street's forecast by $380 million. Gains for the company's space segment helped push overall sales up 0.2% year over year, but the results weren't as strong as anticipated -- and that appears to have had spillover effects for AST's valuation.
What's next for AST?
In addition to Lockheed's Q2 results, new coverage on BlackSky Technology also seems to be playing a role in valuation stumbles for otherwise high-flying space stocks. Clear Street lowered its rating on the stock from buy to hold this morning, and Canaccord lowered its one-year price target from $28 per share to $27 per share despite keeping a buy rating on the stock. The coverage appears to have raised concerns about valuations across the broader space industry, but some emerging news late in the day helped drive some valuation recovery for AST.
According to a report from Reuters today, the Trump administration is ramping up efforts to find partners for the country's "Golden Dome" missile-defense system other than CEO Elon Musk's SpaceX. AST is already rumored to be a tech partner for the Golden Dome project, and it's possible that forthcoming news about the defense initiative could spur substantial gains for the stock.
Should you buy stock in AST SpaceMobile right now?
Before you buy stock in AST SpaceMobile, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and AST SpaceMobile wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $665,092!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,050,477!*
Now, it's worth noting Stock Advisor's total average return is 1,055% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of July 21, 2025
Keith Noonan has no position in any of the stocks mentioned. The Motley Fool recommends Lockheed Martin. The Motley Fool has a disclosure policy.
Why AST SpaceMobile Stock Is Sinking Today was originally published by The Motley Fool
Error al recuperar los datos
Inicia sesión para acceder a tu cartera de valores
Error al recuperar los datos
Error al recuperar los datos
Error al recuperar los datos
Error al recuperar los datos
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
16 minutes ago
- Business Insider
Lockheed Martin awarded $2.06B Missile Defense Agency contract modification
Lockheed Martin (LMT) was awarded a $2.06B modification to a previously awarded contract for the production of Terminal High Altitude Area Defense Interceptors to support the U.S. government. The total value of this contract is increased from $8.35B to $10.42B. Under this modification, the contractor will produce THAAD components under fixed-price incentive contract line-item numbers. The work has an expected completion date Dec. 1, 2029. One offer was solicited, and one offer was received. Fiscal 2024 and fiscal 2025 procurement funds in the amount of $284.92M are being obligated at time of award. The Missile Defense Agency is the contracting activity. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Yahoo
30 minutes ago
- Yahoo
Hologic (HOLX) Reports Q2: Everything You Need To Know Ahead Of Earnings
Medical technology company Hologic (NASDAQ:HOLX) will be reporting earnings this Wednesday afternoon. Here's what investors should know. Hologic met analysts' revenue expectations last quarter, reporting revenues of $1.01 billion, down 1.2% year on year. It was a slower quarter for the company, with a slight miss of analysts' full-year EPS guidance estimates and full-year revenue guidance meeting analysts' expectations. Is Hologic a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Hologic's revenue to be flat year on year at $1.01 billion, slowing from the 2.7% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.05 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Hologic has only missed Wall Street's revenue estimates once over the last two years, exceeding top-line expectations by 0.9% on average. Looking at Hologic's peers in the healthcare equipment and supplies segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Boston Scientific delivered year-on-year revenue growth of 22.8%, beating analysts' expectations by 3.4%, and Intuitive Surgical reported revenues up 21.4%, topping estimates by 3.7%. Boston Scientific traded up 2.9% following the results while Intuitive Surgical was down 1.9%. Read our full analysis of Boston Scientific's results here and Intuitive Surgical's results here. Investors in the healthcare equipment and supplies segment have had steady hands going into earnings, with share prices flat over the last month. Hologic is up 2.8% during the same time and is heading into earnings with an average analyst price target of $69.93 (compared to the current share price of $66.99). Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Sign in to access your portfolio
Yahoo
30 minutes ago
- Yahoo
CONMED (CNMD) Q2 Earnings: What To Expect
Medical tech company CONMED (NYSE:CNMD) will be announcing earnings results this Wednesday after market close. Here's what to look for. CONMED beat analysts' revenue expectations by 2.6% last quarter, reporting revenues of $321.3 million, up 2.9% year on year. It was a very strong quarter for the company, with a solid beat of analysts' full-year EPS guidance estimates and an impressive beat of analysts' EPS estimates. Is CONMED a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting CONMED's revenue to grow 1.9% year on year to $338.3 million, slowing from the 4.5% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.12 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. CONMED has missed Wall Street's revenue estimates three times over the last two years. Looking at CONMED's peers in the healthcare equipment and supplies segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Boston Scientific delivered year-on-year revenue growth of 22.8%, beating analysts' expectations by 3.4%, and Intuitive Surgical reported revenues up 21.4%, topping estimates by 3.7%. Boston Scientific traded up 2.9% following the results while Intuitive Surgical was down 1.9%. Read our full analysis of Boston Scientific's results here and Intuitive Surgical's results here. Investors in the healthcare equipment and supplies segment have had steady hands going into earnings, with share prices flat over the last month. CONMED is down 4% during the same time and is heading into earnings with an average analyst price target of $66.60 (compared to the current share price of $50.02). Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
